Why some CEOs are ditching 5-year plans while others are making 10-year bets

CEOs at TAL Apparel, AT&S and IHH Healthcare are navigating constant disruption from tariffs, supply chain shocks, AI and geopolitical risk. TAL has largely abandoned traditional three- and five-year plans, while AT&S emphasizes financial resilience and long-term investment. IHH Healthcare says planning still needs a 10-year horizon, underscoring a mixed but broadly stable outlook.

Analysis

The important takeaway is not that management teams are “uncertain,” but that planning horizons are bifurcating by business model. Asset-heavy and regulation-sensitive businesses can’t afford the same planning cadence as labor-arbitrage manufacturers: the former need resilience buffers and capex optionality, while the latter can win by shortening decision cycles and keeping cost structures modular. That creates a competitive advantage for operators that can re-source quickly, shift working capital faster, and preserve pricing power without committing to rigid multi-year guidance.

The second-order effect is that constant disruption is compressing the moat of mid-tier suppliers. Tariff shocks and geopolitical friction increase the value of dual sourcing, regional production, and balance-sheet flexibility, which tends to favor larger incumbents and the best-capitalized private operators. Smaller competitors are more likely to get trapped in “expensive flexibility” — paying up for redundancy without enough scale to monetize it — which can pressure margins over the next 6-18 months even if top-line demand stays intact.

AI is the one catalyst that can partially offset these shocks, but only for firms that can turn it into operating leverage rather than pilot projects. The market will likely overpay for generic “AI-enabled” stories and underappreciate boring use cases like procurement optimization, inventory forecasting, and maintenance scheduling, where the payback can show up in 2-4 quarters. In healthcare, the longer planning horizon suggests less sensitivity to near-term noise, but also a higher bar for capital allocation discipline because bad investments compound over years, not quarters.

The contrarian view is that the market may be underestimating how quickly management conservatism becomes strategic advantage. In a world where guidance is less useful, investors should reward companies that under-promise, maintain liquidity, and keep capex flexibility rather than those chasing precision forecasts. The flip side is that any easing in tariffs or geopolitical tension could trigger a sharp relief rally in the most defensive supply-chain beneficiaries, because the valuation support is being built on a persistent-disruption narrative.

Key Decisions for Investors

• Long a basket of high-quality industrials with strong regional production and net cash balance sheets; use a 6-12 month horizon and prefer names trading at a discount to peers despite better supply-chain optionality. Risk/reward: lower downside if disruption persists, with 15-25% upside from multiple re-rating.
• Short or underweight smaller contract manufacturers and low-margin suppliers that lack dual sourcing and pricing power; expect margin pressure over the next 2-4 quarters as redundancy costs rise faster than revenue. Use as a relative-value short against larger-cap peers.
• Long procurement/industrial software beneficiaries of AI-driven cost optimization; focus on firms where AI can cut inventory or sourcing costs within 1-2 reporting cycles. Best expressed as a basket rather than a single name to reduce execution risk.
• In healthcare, prefer capital-disciplined operators with stable reimbursement and long-duration demand over aggressive acquirers; the best setups are names with visible 3-5 year free-cash-flow compounding and limited refinancing need. Hold period: 12+ months.
• If geopolitical/tariff risk fades, take profits quickly on the most crowded “supply-chain resilience” trades; upside could compress in 1-2 quarters as the market reprices from scarcity premium to normalization.